BioTuesdays

Author - Michelle Carr

Aileron Therapeutics Logo
Markets

HCW cuts Aileron Therapeutics PT to $1 from $2

H.C. Wainwright reduced its price target for Aileron Therapeutics (NASDAQ:ALRN) to $1 from $2, but maintained its “buy” rating, after the company reported “underwhelming” interim data from a Phase 1 study in non-small...

June 30, 2022
Neximmune Logo
Markets

Cantor assumes coverage of Neximmune at OW; PT $4

Cantor Fitzgerald analyst Prakhar Agrawal assumed coverage of Neximmune (NASDAQ:NEXI) with an “overweight” rating and price target of $4. The stock closed at $1.61 on June 29. Neximmune is developing a novel T-cell...

June 30, 2022
Aileron Therapeutics Logo
Markets

WB cuts Aileron Therapeutics to market perform

William Blair downgraded Aileron Therapeutics (NASDAQ:ALRN) to “market perform” after the company released interim data from a Phase trial of ALRN-6924 as a chemoprotectant in patients with non-small cell lung cancer...

June 29, 2022
Akoya Logo
Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022
Markets

Maxim starts Femasys at buy; PT $5

Maxim Group launched coverage of Femasys (NASDAQ:FEMY) with a “buy” rating and $5 price target. The stock closed at $1.30 on June 16. Femasys is developing treatments to address the two extremes of the women’s...

June 17, 2022